In earnings call, Hims CEO addresses scrutiny of GLP-1 compounding CEO emphasized the company’s other offerings and potential for branded deals By Katie PalmerFeb. 23, 2026 Health Tech Correspondent

https://www.statnews.com/2026/02/23/him-hers-earnings-2026-outlook-compounded-semaglutide/